These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 5003621)

  • 21. The effect of dibromodulcitol (NSC 104800) on intravenously induced cytemia of rats.
    Németh L
    Neoplasma; 1971; 18(5):533-7. PubMed ID: 5119525
    [No Abstract]   [Full Text] [Related]  

  • 22. Chemotherapy research nurse.
    Hubbard S; Devita V
    Am J Nurs; 1976 Apr; 76(4):560-5. PubMed ID: 818899
    [No Abstract]   [Full Text] [Related]  

  • 23. Potential antitumor agents. Some 1,6-disubstituted galactitol and mannitol derivatives.
    Acton EM; Keyanpour-Rad M; Christensen JE; Tong HH; Kwok RP; Goodman L
    Carbohydr Res; 1972 May; 22(2):477-86. PubMed ID: 5047748
    [No Abstract]   [Full Text] [Related]  

  • 24. Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's disease.
    DeConti RC; Mitchell MS; Marsh JC; Bertino JR
    Cancer Chemother Rep; 1971 Dec; 55(5):607-10. PubMed ID: 4946083
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II trial of dianhydrogalactitol in the treatment of children with refractory childhood malignancies: a report from the Children's Cancer Study Group.
    Finklestein JZ; Shore N; Krivit W; Hammond D; Higgins G
    Cancer Treat Rep; 1985 Nov; 69(11):1331-3. PubMed ID: 4092198
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313).
    Németh L; Institóris L; Somfai S; Gál F; Pályi I; Sugár J; Csuka O; Szentirmay Z; Kellner B
    Cancer Chemother Rep; 1972 Oct; 56(5):593-602. PubMed ID: 4652589
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Ahmann DL; O'Connell MJ; Bisel HF; Edmonson JH; Hahn RG; Frytak S
    Cancer Treat Rep; 1977; 61(1):81-2. PubMed ID: 324622
    [No Abstract]   [Full Text] [Related]  

  • 28. Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.
    Institóris E; Szikla K; Otvös L; Gál F
    Cancer Chemother Pharmacol; 1989; 24(5):311-3. PubMed ID: 2758560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical toxicology of alpha-2'-deoxythioguanosine (NSC-71851).
    Henry MC; DiDomenico E
    Cancer Chemother Rep 3; 1974 Sep; 5(1):9-14. PubMed ID: 4213304
    [No Abstract]   [Full Text] [Related]  

  • 30. The absorption and metabolism of dibromodulcitol in patients with advanced cancer.
    Belej MA; Troetel WM; Weiss AJ; Stambaugh JE; Manthei RW
    Clin Pharmacol Ther; 1972; 13(4):563-72. PubMed ID: 5042371
    [No Abstract]   [Full Text] [Related]  

  • 31. Auto-immune haematological complications occurring during the treatment of malignant lymphoproliferative diseases.
    Ludwin D; Sacks P; Lynch S; Jacobs P; Bezwoda W; Bothwell TH
    S Afr Med J; 1974 Oct; 48(51):2143-5. PubMed ID: 4479692
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.
    Edmonson JH; Frytak S; Letendre L; Kvols LK; Eagan RT
    Cancer Treat Rep; 1979; 63(11-12):2081-3. PubMed ID: 526941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.
    Eagan RT; Ingle JN; Frytak S; Rubin J; Kvols LK; Carr DT; Coles DT; O'Fallon JR
    Cancer Treat Rep; 1977 Oct; 61(7):1339-45. PubMed ID: 589599
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase I study of a five-day intermittent schedule for 1,2:5,6-dianhydrogalactitol (NSC-132313).
    Eagan RT; Moertel CG; Hahn RG; Schutt AJ
    J Natl Cancer Inst; 1976 Jan; 56(1):179-81. PubMed ID: 943554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I evaluation of the combination 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) and dianhydrogalactitol (DAG; NSC-132313) in patients with advanced neoplastic diseases.
    Creagan ET; Eagan RT; Rubin J
    Med Pediatr Oncol; 1979; 7(2):179-80. PubMed ID: 502975
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU.
    Young RC; DeVita VT; Serpick AA; Canellos GP
    N Engl J Med; 1971 Aug; 285(9):475-9. PubMed ID: 5558887
    [No Abstract]   [Full Text] [Related]  

  • 37. Preliminary pharmacological studies with 1,6-dimesyl-2,3-4,5-dianhydro-L-iditol in patients with cancer.
    Csetényi J; Bihari V; Számel SI; Horváth IP; Eckhardt S
    Eur J Cancer (1965); 1975 Sep; 11(9):675-6. PubMed ID: 176030
    [No Abstract]   [Full Text] [Related]  

  • 38. Initial clinical trials with 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NCS-112682).
    Luce JK; Bodey GP
    Cancer Chemother Rep; 1970 Apr; 54(2):131-4. PubMed ID: 4946003
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical experience with a new anticancer agent, carbazilquinone (NSC-134679).
    Saito T; Oira S; Wakui A; Yokoyama M; Takahashi H
    Cancer Chemother Rep; 1973; 57(4):447-57. PubMed ID: 4586952
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II study of dibromodulcitol (NSC-104800).
    Andrews NC; Weiss AJ; Wilson W; Nealon T
    Cancer Chemother Rep; 1974; 58(5 Pt 1):653-60. PubMed ID: 4426045
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.